Expert Interview
Discussing Pfizer's Phase 3 results for BRAFTOVI in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.
Ticker(s): PFEInstitution: Duke University
- Gastrointestinal Oncologist and Professor of Medicine in the Department of Surgery at Duke University
- Manages 50+ patients a year with colorectal cancer
- Research interest in immune therapies for treating GI cancers
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
